# A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

> **NCT02871401** · PHASE1 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 31 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Valganciclovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02871401
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-03
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-01-31
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02871401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02871401, "A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02871401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*